(S)-Veliflapon

Modify Date: 2024-04-03 10:17:58

(S)-Veliflapon structure	Common Name	(S)-Veliflapon
	CAS Number	128253-32-7	Molecular Weight	361.43
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₃H₂₃NO₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of (S)-Veliflapon

(S)-Veliflapon ((S)-BAY X 1005; (S)-DG-031) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood[1][2][3].

Name	(S)-Veliflapon

Description	(S)-Veliflapon ((S)-BAY X 1005; (S)-DG-031) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood[1][2][3].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> FLAP Signaling Pathways >> GPCR/G Protein >> Leukotriene Receptor Research Areas >> Inflammation/Immunology
In Vitro	(S)-Veliflapon 以剂量依赖性方式减少了人全血中白三烯 B4 (LTB4) 的合成[1]。
References	[1]. Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95. [2]. Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746. [3]. Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment and prophylaxis therapy. United States. US20070280917.

Molecular Formula	C₂₃H₂₃NO₃
Molecular Weight	361.43

(S)-Veliflapon

Use of (S)-Veliflapon

Names

(S)-Veliflapon Biological Activity

Chemical & Physical Properties